Get started
Glenmark Pharmaceuticals LimitedGlenmark Pharmaceuticals LimitedGlenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsOptionsETFs
Full chart
Full chart

Compare with Glenmark Pharmaceuticals Limited



Key stats


Market capitalization
‪645.39 B‬ INR
Dividend yield (indicated)
0.22%
Price to earnings Ratio (TTM)
35.90
Basic EPS (TTM)
63.70 INR
Net income (FY)
‪13.62 B‬ INR
Revenue (FY)
‪169.83 B‬ INR
Shares float
‪144.02 M‬
Beta (1Y)
0.33

Latest earnings


Last report date
Jul 31, 2026
Report period
Q1 2026
EPS
17.11 INR
Revenue
‪40.18 B‬ INR
Earnings call summary

Q1 FY2026 saw modest consolidated revenue growth, strong India and North America performance, and robust launches in oncology and diabetes. Gross margin remains strong at 68-69%, with EBITDA margin expected to stabilize at 23%+ from Q3. Net debt stands at INR 1,500 crore.

Details


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Glenn Mario Saldanha
Website
glenmarkpharma.com
Headquarters
Mumbai
Founded
1977
IPO date
Dec 10, 1999
ISIN
INE935A01035
FIGI
BBG000BJ3V03
Identifiers
ISIN INE935A01035
CFI code
ESVUFN
Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture, and marketing of pharmaceutical products. It operates through the following geographical segments: India, North America, Europe, Latin America, and Rest of the World. The company was founded by Gracias Saldanha on November 18, 1977 and is headquartered in Mumbai, India.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


VWO
Vanguard FTSE Emerging Markets ETF
Weight0.03%
Market value‪46.52 M‬
IEMG
iShares Core MSCI Emerging Markets ETF
Weight0.02%
Market value‪38.17 M‬
EIMI
iShares Core MSCI EM IMI UCITS ETF
Weight0.03%
Market value‪12.43 M‬
EIMU
iShares Core MSCI EM IMI UCITS ETF
Weight0.03%
Market value‪12.43 M‬
AVEM
Avantis Emerging Markets Equity ETF
Weight0.04%
Market value‪11.68 M‬
SMIN
Ishares MSCI India Small Cap ETF
Weight0.92%
Market value‪7.11 M‬
PHARMABEES
Nippon India Nifty Pharma ETF Units Exchange Traded Fund
Weight3.40%
Market value‪6.02 M‬
FID
Franklin FTSE India Index ETF Trust Units
Weight0.20%
Market value‪5.38 M‬
FLIN
Franklin FTSE India ETF
Weight0.19%
Market value‪5.31 M‬
SPEM
State Street SPDR Portfolio Emerging Markets ETF
Weight0.03%
Market value‪4.62 M‬
FLXI
Franklin LibertyShares ICAV - FTSE India UCITS ETF
Weight0.21%
Market value‪4.50 M‬

Explore more ETFs 

Frequently asked questions


The current price of GLENMARK is 2,282.00 INR — it has increased by 0.39% in the past 24 hours. Watch Glenmark Pharmaceuticals Limited stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BSE exchange Glenmark Pharmaceuticals Limited stocks are traded under the ticker GLENMARK.
GLENMARK stock has risen by 1.17% compared to the previous week, the month change is a −0.17% fall, over the last year Glenmark Pharmaceuticals Limited has showed a 12.69% increase.
We've gathered analysts' opinions on Glenmark Pharmaceuticals Limited future price: according to them, GLENMARK price has a max estimate of 2,750.00 INR and a min estimate of 2,100.00 INR. Watch GLENMARK chart and read a more detailed Glenmark Pharmaceuticals Limited stock forecast: see what analysts think of Glenmark Pharmaceuticals Limited and suggest that you do with its stocks.
GLENMARK reached its all-time high on Apr 29, 2026 with the price of 2,471.05 INR, and its all-time low was 19.65 INR and was reached on Nov 5, 2003. View more price dynamics on GLENMARK chart.
See other stocks reaching their highest and lowest prices.
GLENMARK stock is 2.29% volatile and has beta coefficient of 0.33. Track Glenmark Pharmaceuticals Limited stock price on the chart and check out the list of the most volatile stocks — is Glenmark Pharmaceuticals Limited there?
Today Glenmark Pharmaceuticals Limited has the market capitalization of ‪645.39 B‬, it has decreased by −0.61% over the last week.
Yes, you can track Glenmark Pharmaceuticals Limited financials in yearly and quarterly reports right on TradingView.
Glenmark Pharmaceuticals Limited is going to release the next earnings report on Nov 6, 2026. Keep track of upcoming events with our Earnings Calendar.
Glenmark Pharmaceuticals Limited revenue for the last quarter amounts to ‪40.18 B‬ INR, despite the estimated figure of ‪39.16 B‬ INR. In the next quarter, revenue is expected to reach ‪40.03 B‬ INR.
GLENMARK net income for the last quarter is ‪4.83 B‬ INR, while the quarter before that showed ‪3.01 B‬ INR of net income which accounts for 0.00% change. Track more Glenmark Pharmaceuticals Limited financial stats to get the full picture.
Yes, GLENMARK dividends are paid semi-annually. The last dividend per share was 2.50 INR. As of today, Dividend Yield (TTM)% is 0.00%. Tracking Glenmark Pharmaceuticals Limited dividends might help you take more informed decisions.
Glenmark Pharmaceuticals Limited dividend yield was 0.23% in 2025, and payout ratio reached 10.36%. The year before the numbers were 0.16% and 6.74% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Glenmark Pharmaceuticals Limited EBITDA is ‪42.07 B‬ INR, and current EBITDA margin is 26.92%. See more stats in Glenmark Pharmaceuticals Limited financial statements.
Like other stocks, GLENMARK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Glenmark Pharmaceuticals Limited stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Glenmark Pharmaceuticals Limited technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Glenmark Pharmaceuticals Limited stock shows the buy signal. See more of Glenmark Pharmaceuticals Limited technicals for a more comprehensive analysis.